DNLI stock news
This page provides real-time market news, earnings updates, and company announcements related to Denali Therapeutics Inc. (DNLI).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-15 17:43 EST
The Increasing Expenses of Dementia Treatment and Their Influence on Healthcare Investment Prospects
Bitget-RWA2025-12-04 00:38:08
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Finviz2026-02-26 21:03:46
Denali Therapeutics Inc. announced that its new drug Avlayah will soon be available on the US market after receiving regulatory approval.
老虎证券2026-03-25 16:01:12
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
Finviz2026-03-26 20:09:54
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Finviz2026-04-03 17:36:43
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Finviz2026-04-09 12:03:53
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Finviz2026-04-03 17:36:43
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Finviz2026-04-09 12:03:53
DNLI stock chart
DNLI stock detailsDNLI stock price change
On the last trading day, DNLI stock closed at 19.42 USD, with a price change of 0.99% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more